Piper Sandler Issues Pessimistic Forecast for TransMedics Group (NASDAQ:TMDX) Stock Price

TransMedics Group (NASDAQ:TMDX) had its price objective reduced by Piper Sandler from $110.00 to $90.00 in a research report released on Wednesday,Benzinga reports. Piper Sandler currently has an overweight rating on the stock.

Other analysts also recently issued reports about the stock. Baird R W upgraded shares of TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a report on Tuesday, December 3rd. Canaccord Genuity Group lowered their target price on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a report on Wednesday, November 20th. TD Cowen lowered their target price on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a report on Monday, November 18th. Finally, JPMorgan Chase & Co. lowered their target price on shares of TransMedics Group from $173.00 to $116.00 and set an “overweight” rating on the stock in a report on Tuesday, October 29th. Two research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, TransMedics Group has an average rating of “Moderate Buy” and a consensus target price of $126.80.

TransMedics Group Stock Performance

Shares of TMDX stock opened at $64.26 on Wednesday. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The company has a market capitalization of $2.16 billion, a P/E ratio of 68.36 and a beta of 2.06. The company’s 50 day moving average price is $97.26 and its two-hundred day moving average price is $131.98. TransMedics Group has a 52 week low of $63.42 and a 52 week high of $177.37.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The company had revenue of $108.76 million for the quarter, compared to analyst estimates of $115.00 million. During the same quarter last year, the business posted ($0.12) earnings per share. The business’s quarterly revenue was up 63.7% on a year-over-year basis. On average, analysts expect that TransMedics Group will post 1 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Edward M. Basile sold 6,750 shares of the company’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total value of $563,962.50. Following the completion of the transaction, the director now owns 732 shares of the company’s stock, valued at $61,158.60. This represents a 90.22 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Tamer I. Khayal sold 2,958 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $148.24, for a total value of $438,493.92. Following the completion of the transaction, the insider now directly owns 20,843 shares of the company’s stock, valued at $3,089,766.32. This represents a 12.43 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 28,042 shares of company stock valued at $3,563,985 over the last quarter. 7.00% of the stock is owned by company insiders.

Institutional Trading of TransMedics Group

Several institutional investors have recently added to or reduced their stakes in the stock. Driehaus Capital Management LLC boosted its holdings in TransMedics Group by 15.8% in the second quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock valued at $223,832,000 after acquiring an additional 202,867 shares during the last quarter. Geode Capital Management LLC boosted its holdings in TransMedics Group by 1.3% in the third quarter. Geode Capital Management LLC now owns 763,790 shares of the company’s stock valued at $119,938,000 after acquiring an additional 10,106 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in TransMedics Group by 5.3% in the third quarter. Allspring Global Investments Holdings LLC now owns 599,116 shares of the company’s stock valued at $94,061,000 after acquiring an additional 30,092 shares during the last quarter. Vaughan Nelson Investment Management L.P. boosted its holdings in TransMedics Group by 24.3% in the third quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company’s stock valued at $51,654,000 after acquiring an additional 64,360 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in TransMedics Group by 2.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company’s stock valued at $42,656,000 after acquiring an additional 6,634 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.